Skip to main content
. 2021 Feb 13;73(6):949–956. doi: 10.1093/cid/ciab121

Figure 2. .

Figure 2. 

Recombinant zoster vaccine effectiveness by age, sex, race/ethnicity, and region from 2018 to 2019. aValues are reported as percentages. bVaccine effectiveness was adjusted using inverse probability weighting for age, sex, race, region, prior zoster vaccine live, antiviral use, healthcare utilization, and Charlson comorbidity index. cThe unknown race/ethnicity category includes individuals with either unknown or missing race/ethnicity. Abbreviation: CI, confidence interval.